• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

An Update on GLP-1 Receptor Agonists.

作者信息

Bloomgarden Zachary

机构信息

Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出版信息

J Diabetes. 2025 Aug;17(8):e70147. doi: 10.1111/1753-0407.70147.

DOI:10.1111/1753-0407.70147
PMID:40842408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12371248/
Abstract
摘要

相似文献

1
An Update on GLP-1 Receptor Agonists.胰高血糖素样肽-1受体激动剂的最新进展。
J Diabetes. 2025 Aug;17(8):e70147. doi: 10.1111/1753-0407.70147.
2
Impact of GLP-1 receptor agonists on upper gastrointestinal endoscopy: an updated systematic review and meta-analysis.胰高血糖素样肽-1受体激动剂对上消化道内镜检查的影响：一项更新的系统评价和荟萃分析。
Surg Endosc. 2025 Jul 9. doi: 10.1007/s00464-025-11962-4.
3
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
4
Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.GLP-1 激动剂和 SGLT-2 抑制剂对糖尿病视网膜病变进展的影响：一项汇总电子健康记录数据研究。
Am J Ophthalmol. 2024 Sep;265:39-47. doi: 10.1016/j.ajo.2024.04.010. Epub 2024 Apr 17.
5
Long-Term Impact of GLP-1 Receptor Agonists on AF Recurrence After Ablation in Obese Patients.胰高血糖素样肽-1受体激动剂对肥胖患者消融术后房颤复发的长期影响。
J Cardiovasc Electrophysiol. 2025 May 23. doi: 10.1111/jce.16737.
6
Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence.GLP-1 激动剂和 SGLT2 抑制剂在妊娠和哺乳期对后代结局的影响：证据的系统评价。
Front Endocrinol (Lausanne). 2023 Oct 10;14:1215356. doi: 10.3389/fendo.2023.1215356. eCollection 2023.
7
The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes.胰高血糖素样肽-1激动剂对1型糖尿病患者糖化血红蛋白和胰岛素剂量的影响。
Front Endocrinol (Lausanne). 2025 Aug 7;16:1550938. doi: 10.3389/fendo.2025.1550938. eCollection 2025.
8
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
9
Treatment discontinuation among users of GLP-1 receptor agonists and SGLT2 inhibitors in a national population of individuals with type 2 diabetes.在全国2型糖尿病患者群体中，GLP-1受体激动剂和SGLT2抑制剂使用者的治疗中断情况。
Diabetologia. 2025 May 2. doi: 10.1007/s00125-025-06439-x.
10
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.

本文引用的文献

1
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study.真实世界临床实践中2型糖尿病患者对胰高血糖素样肽-1受体激动剂反应的异质性：来自糖尿病患者虚拟队列研究（DPV注册研究）——一项IMI-SOPHIA研究的见解
Diabetologia. 2025 May 22. doi: 10.1007/s00125-025-06448-w.
2
Glucagon-like peptide-1 receptor agonists lower risk of cardiovascular and non-cardiovascular mortality: A meta-analysis of eleven cardiovascular outcome trials.胰高血糖素样肽-1受体激动剂降低心血管和非心血管死亡率风险：十一项心血管结局试验的荟萃分析。
Diabetes Obes Metab. 2025 Jul;27(7):4017-4021. doi: 10.1111/dom.16424. Epub 2025 May 8.
3
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.司美格鲁肽治疗代谢功能障碍相关脂肪性肝炎的3期试验
N Engl J Med. 2025 Jun 5;392(21):2089-2099. doi: 10.1056/NEJMoa2413258. Epub 2025 Apr 30.
4
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists.胰高血糖素样肽-1受体激动剂在代谢功能障碍相关脂肪性肝炎患者中的多效性作用：胃肠病学家的综述
Expert Opin Investig Drugs. 2025 Mar;34(3):169-195. doi: 10.1080/13543784.2025.2473062. Epub 2025 Mar 17.
5
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.肠促胰岛素药物对超重或肥胖且患有/未患有2型糖尿病的成年人血糖控制、体重和血压的比较疗效：一项系统评价和网状荟萃分析
Front Endocrinol (Lausanne). 2025 Feb 4;16:1513641. doi: 10.3389/fendo.2025.1513641. eCollection 2025.
6
GLP-1 Agonists as Potential Neuromodulators in Development of Parkinson's Disease: A Nationwide Cohort Study.胰高血糖素样肽-1激动剂作为帕金森病发展中潜在的神经调节剂：一项全国性队列研究。
Eur J Neurol. 2025 Feb;32(2):e70075. doi: 10.1111/ene.70075.
7
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.胰高血糖素样肽-1受体激动剂对心血管事件和危险因素的疗效及安全性比较：一项综述与网状Meta分析
Diabetes Obes Metab. 2025 Apr;27(4):1735-1751. doi: 10.1111/dom.16228. Epub 2025 Feb 5.
8
Mapping the effectiveness and risks of GLP-1 receptor agonists.绘制胰高血糖素样肽-1受体激动剂的有效性和风险图谱。
Nat Med. 2025 Mar;31(3):951-962. doi: 10.1038/s41591-024-03412-w. Epub 2025 Jan 20.
9
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.用于治疗阻塞性睡眠呼吸暂停的胰高血糖素样肽-1受体激动剂：一项荟萃分析。
Sleep. 2025 Apr 11;48(4). doi: 10.1093/sleep/zsae280.
10
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.一种还是两种？钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）或胰高血糖素样肽-1受体激动剂（GLP1RA）联合治疗与单药治疗的心肾效应比较
Diabetes Obes Metab. 2025 Feb;27(2):806-815. doi: 10.1111/dom.16078. Epub 2024 Nov 21.